Latest Epigenetics biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

ORYZON to present positive preclinical efficacy data of ORY-4001 in Charcot-Marie-Tooth (CMT) disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

by Oryzon Genomics

11 months ago
ORY-4001, Charcot-Marie-Tooth (CMT) disease

Oryzon announced today that it will present positive preclinical efficacy data of ORY-4001 in a CMT model at the 2023 Peripheral Nerve Society (PNS) Annual Meeting, which will be held June 17-20 at th...

ibs.GRANADA scientists discover that an important protein in tumor prevention is epigenetically silenced in some leukemias

by Instituto de Investigación Biosanitaria - Ibs Granada

11 months ago
leukemia, Epigenetic silencing, BCL7A protein

It has been identified that the cells of some leukemias silence the production of the BCL7A protein, a protein that helps prevent cells from becoming tumorous.

Presente y futuro de la medicina de precisión en enfermedades raras

by Revista Genética Médica

11 months ago
secuenciación de genomas completos, enfermedades raras, medicina de precisión

Nuevas oportunidades para la medicina de precisión plantean la atención de los pacientes desde una perspectiva personalizada, considerando sus características clínicas, genéticas y de estilo de v...

Positive preclinical data of ORY-4001 for the treatment of Charcot-Marie-Tooth (CMT) disease presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

by Oryzon Genomics

10 months ago
Charcot-Marie-Tooth (CMT), ORY-4001, histone deacetylase 6 (HDAC-6)

Oryzon Genomics, S.A., presented yesterday positive preclinical efficacy data of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor

Atherosclerosis accelerates aging

by Centro Nacional de Investigaciones Cardiovasculares - CNIC

10 months ago
Atherosclerosis, Epigenetic age

A new CNIC study shows that low-grade systemic inflammation triggered by subcinical atherosclerosis accelerates epigenetic aging in otherwise healthy young individuals

Researchers reveal how cells rewrite their fate

by Centre for Genomic Regulation

10 months ago
cell fate conversion, C/EBPα

Researchers at the Centre for Genomic Regulation (CRG) in Barcelona and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Berlin reveal how cells accelerate changes to th...

La Enfermedad Inflamatoria Intestinal podría tener un origen epigenético

by Instituto de Investigación Marqués de Valdecilla

10 months ago
enfermedad inflamatoria intestinal (IBD), ADN citoplasmáticos, HP1γ

Los procesos inflamatorios crónicos en el intestino provocan afecciones graves como la enfermedad inflamatoria intestinal (IBD) y el cáncer. En un estudio internacional en el que han colaborado inve...

3.2 million euros to identify new genetic variants responsible for hereditary cancers

by IDIBELL - Institut d’Investigació Biomèdica de Bellvitge

10 months ago
IMPaCT_VUSCan, hereditary cancers

The project will carefully examine the genetic information, gene expression patterns and DNA modifications (epigenetics) of 300 families in Spain selected for having a high-risk family or personal his...

IDIBELL participates in a €10M European project to prevent childhood obesity

by IDIBELL - Institut d’Investigació Biomèdica de Bellvitge

10 months ago
childhood obesity, EprObes project

With a budget of 10 million euros, the European project "EprObes", which stands for Lifelong Obesity Prevention through Risk Factor Identification, Prognosis and Early Intervention" will address the p...

Novel p53-mediated mechanism of lung cancer suppression by cell differentiation promises a new route for therapy

by VHIO

9 months ago
p53, AT1, lung adenocarcinoma

Findings from a study published in Nature (1) show that the TP53 gene governs differentiation of pulmonary alveolar type 1 (AT1) cells, but when mutated it loses its function, resulting in abnormal ce...

ORYZON reports financial results and corporate updates for half-year ending June 30, 2023

by Oryzon Genomics

9 months ago
vafidemstat in CNS, ORYZON

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the hal...

Oryzon announces completed patient recruitment in the PORTICO Phase IIb trial of vafidemstat in Borderline Personality Disorder

by Oryzon Genomics

9 months ago
Borderline Personality Disorder (BPD), vafidemstat

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reports that full patient recruitment ...